GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
Taking the fun out of weed, but addressing unmet need: Startup refining cannabinoids for therapeutic use
Los Angeles startup Kalytera Therapeutics is taking the high out of the THC – refining cannabinoids so they can have broader therapeutic applications in conditions like osteoporosis, Prader-Willi syndrome, PTSD, obesity and weight loss associated with cancer. Kalytera just raised $500,000 in seed funding, according to a regulatory filing. There’s a litany of potential applications for […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.